Flunarizine- & -Cinnarizine-Induced Extrapyramidal Reactions
Neurol 37:881-884, Micheli,F.,et al, 1987
Aggravation of Parkinson's Disease by Cinnarizine
JNNP 50:804-805, Marti-Masso,J.F.,et al, 1987
Classification of Parkinsonism
in Handbook of Parkinson's Disease, Marcel Dekker, Inc, New York, Ch 3, p 61., Koller,W.C., 1987
Metoclopramide-Induced Parkinsonism in Hemodialysis Patients
Arch Int Med 146:2070-2071, Sirota,R.A.,et al, 1986
Locus Ceruleus Lesions & Eosinophilic Inclusions in MPTP-Treated Monkeys
Ann Neurol 20:449-455, Forno,L.S.,et al, 1986
Parkinsonism, Tardive Dyskinesia, Akathisia, & Depression Induced by Flunarizine
Lancet 1:1303-1304, Chouza,C.,et al, 1986
The Neuroleptic Malignant Syndrome:Agent and Host Interaction
Acta Psychiatr Scand 73:337-347, Shaley,A.&Munitz,H., 1986
Reversible Parkinsonism Related to Meperidine
NEJM 312:509, Lieberman,A.N.,et al, 1985
The Clinical Syndrome of Striatal Dopamine Deficiency, Parkinsonism Induced by MPTP
NEJM 312:1418-1421, Burns,R.S.,et al, 1985
Permanent Human Parkinsonism Due to 1-Methyl-4-Phenyl-1, 2, 3, 6-Tetrahydropyridine (MPTP) :Seven Cases
Neurol 35:949-956, Ballard,P.A.,et al, 1985
Extrapyramidal Reactions with Metoclopramide
BMJ 291:930-932, Bateman,D.N.,et al, 1985
Drug-Induced Parkinsonism in the Elderly
Lancet 2:1082-1083, Stephen,P.J.,et al, 1984
Chronic Parkinsonism Secondary to Intranasal Administration of a Product of Meperidine-Analogue Synthesis
NEJM 310:325, Wright,J.M.,et al, 1984
Parkinson's Disease in a Chemist Working with l-Methyl-4-Phenyl-1, 2, 5, 6-Tetrahydropyridine
NEJM 309:310, Langston,J.W.,et al, 1983
Metoclopramide-Induced Parkinsonism
Arch Neurol 39:494-496, Indo,T.,et al, 1982
A Danger In Making The Diagnosis Of Parkinson's Disease
Lancet 1:1212-1213, Murdoch,P.S.,et al, 1982
Reversible Drug-Induced Parkinsonism
Arch Neurol 39:644-646, Rajput,A.H.,et al, 1982
Extrapyramidal Side-Effects Of Metoclopramide
Lancet 2:1254-1255, Kataria,M.,et al, 1981
Parkinsonism & Tardive Dyskinesia Associated With Long-Term Metoclopramide Therapy
NEJM 305:1417, Grimes,J.D., 1981
Nervous System Toxicity of Chemo Agents
Young, DF, in Vinken PJ, Bruyn GW, Handbook of Clin Neurol, North-Holland Publ Co, Amster, Vol 39, 1, 80, p 104, 1980
Exacerbation of Parkinsonism by Methyldopa
JAMA 244:2727-2728, Rosenblum,A.M.&Montgomery,E.B., 1980
Methamphetamine-Induced Basal Ganglia Toxicity Presenting as Parkinsonism
Neurol 104:e213365, Yi,M.Y.,et al, 2025
Juvenile-Onset Dopa-Responsive Dystonia-Until It Isnt
Neurol 104:e213436, Paredes,N.C.,et al, 2025
Seizures, Driver Licensure, and Medical Reporting
Neurol 104:e213459, Tolchin,B.,et al, 2025
Long-Term Consumption of Ultraprocessed Foods and Prodromal Features of Parkinson Disease
Neurol 104:e213562, Wang,P.,et al, 2025
Safety and Efficacy of Staged, Bilateral Focused Ultrasound Thalamotomy in Essential Tremor, An Open-Label Clinical Trial
JAMA Neurol 81:939-946, Kaplitt,M.G.,et al, 2024
Association of Coffee Consumption and Prediagnostic Caffeine Metabolites with Incident Parkinson Disease in a Population-Based Cohort
Neurol 102:e209201, Zhao,Y.,et al, 2024
Treatment Modalities and Outcomes in Brainstem Cavernous Malformations: A Large Multicenter Observational Cohort Study
Stroke 55:1151-1160, Lu,J.,et al, 2024
Vascular Malformations of the Central Nervous System
www.UptoDate.Com, March, Singer,R.J.,et al, 2024
Parkinsons Disease
NEJM 391:442-452, Tanner,C.M. & Ostrem,J.L., 2024
Cold-Induced Reflex Epilepsy
JAMA Neurol 81:882-883, Li,C.M.F.,et al, 2024
SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes
Neurol 103:e209805, Kim,H.K.,et al, 2024
A Young Woman With Hypertonia, Severe Scoliosis, and Encephalopathy
JAMA Neurol 81:83-84, Hua,L.,et al, 2024
Seizures When Exiting a Bath, A Rare Type of Reflex Epilepsy
Neurol 103:e210025, Pascarella,A.,et al, 2024
MR Imaging Patterns and Prognosis in Powassan Virus Encephalitis
Neurologist doi.10.1097/NRI.0000000000000533, Finelli,P.F., 2023
Trial of Globus Pallidus Focused Ultrasound Ablation in Parkinsons Disease
NEJM 388:683-693, 759, Krishna,V.,et al, 2023
Cutaneous a-Synuclein Signatures in Patients with MultipleSystem Atrophy and Parkinson Disease
Neurol 100:e1529-e1539, Gibbons,C.,et al, 2023
Genetic Causes of Cerebral Small Vessel Diseases, A Parctical Guide for Neurologists
Neurol 100:766-783, Manini,A.,&Pantoni,L., 2023
Risk of Parkinson Disease Among Service Members at Marine Corps Base Camp Lejeune
JAMA Neurol 80:673-681, Goldman,S.M.,et al, 2023
Whether Mindfulness-Guided Therapy Can Be a New Direction for the Rehabilitation of Patients with Parkinsons Disease:A Network Meta-Analysis of Non-pharmacological Alternative Motor-/Sensory-Based Interventions
Front Psychol doi:10.3389/fpsyg.2023.11625/4j2023, He,S.,et al, 2023
Glial Fibrillary Acidic Protein Autoimmunity
Neurol 98:e653-e668, Gravier-Dumonceau, A.,et al, 2022
A 6-Year-Old Girl with Progressive Toe Walking
Neurol 98:e769-e773, Libdeh, A.A. & Ibrahim, A., 2022
Reversible Parkinsonism Caused by Lumboperitoneal Shunt Overdrainage
Neurol 99:486-488, Takeuchi, H.,et al, 2022
Neuroimaging Biomarkers in a Patient with Probable Psychiatric-Onset Prodromal Dementia with Lewy Bodies
Neurol 99:654-657, Urso, D.,et al, 2022
The Phenotypic Continuum of ATP1A3-Related Disorders
Neurol 99:e1511-e1526, Vezyroglou,A., et al, 2022
Complete Evaluation of Dementia: PET and MRI Correlation and Diagnosis for the Neuroradiologist
AJNR 42:998-1007, Oldan, J.D.,et al, 2021
Clinical and Genetic Features in Patients with Reflex Bathing Epilepsy
Neurol 97:e577-e586, Accogli, A.,et al, 2021
Single Photon Emission Computed Tomography/Positron Emission Tomography Molecular Imaging for Parkinsonism: A Fast-Developing Field
Ann Neurol 90:711-719, Verger, A.,et al, 2021
Changing Gears - DBS for Dopaminergic Desensitization in Parkinsons Disease?
Ann Neurol 90:699-710, Weiss, D.,et al, 2021
A Middle-Aged Man with Progressive Gait Abnormalities
Neurol 97:e2423-e2428, Lin, J.,et al, 2021